SOURCE: Equity News Circuit

Equity News Circuit

February 25, 2013 08:15 ET

Free Research Reports on AIG, AVG, FRO and VVUS Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Feb 25, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

American International Group, Inc. (NYSE: AIG) shares surged 3.14 percent on 47.6 million shares traded to close at $38.45 a share Friday. The company reported an operating profit of $0.20 a share for the fourth quarter, topping analysts' estimates of a loss of $0.08 a share, according to Bloomberg.

Find out more about American International Group including full access to the free equity report at: www.BedfordReport.com/AIG

AVG Technologies NV (NYSE: AVG) shares surged 14.1 percent on 3.52 million shares traded Friday, which was nearly six times the average daily volume. The company reported a net income of $4.9 million, or $0.09 per diluted share, for the fourth quarter, compared to a net loss of $0.03 a share a year ago.

Find out more about AVG Technologies including full access to the free equity report at: www.BedfordReport.com/AVG

Frontline Ltd. (NYSE: FRO) shares declined 13.45 percent on nearly 3 million shares traded Friday to close at $2.51 a share. The company warned that if the tanker market does not recover by 2015 "Frontline will not have sufficient cash to repay the existing $225 million convertible bond loan at maturity in April 2015."

Find out more about Frontline including full access to the free equity report at: www.BedfordReport.com/FRO

VIVUS, Inc. (NASDAQ: VVUS) shares of the anti-obesity drug maker declined 2.32 percent to close at 12.58 a share Friday. The company announced that the European Medicines Agency confirmed their previous decision to decline the Marketing Authorization Application for Qsiva. Qsiva was approved by the FDA in July 2012 and is sold under the trade name Qsymia.

Find out more about VIVUS including full access to the free equity report at: www.BedfordReport.com/VVUS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information